Real-World data reveals how lung cancer patients fare on Triple-Drug combo

NCT ID NCT05599685

Completed Knowledge-focused Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 302 patients with advanced non-small cell lung cancer in Greece who were treated with a combination of nivolumab, ipilimumab, and chemotherapy as their first therapy. Researchers tracked patient characteristics, treatment patterns, and survival rates over time. The goal was to see how this treatment performs in real-world settings, outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab, ipilimumab, and platinum-based chemotherapy
What this could lead to: If successful, this study could help doctors understand how well this drug combination works outside of clinical trials, potentially improving treatment guidelines for metastatic lung cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient differences and real-world variability. It does not test a new treatment or prove effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Local Institution - 0001

Athens, 15561, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.